Biotech is the Next Big Squeeze.
These are the names to watch.

A historic squeeze in the biotechnology industry is brewing, and few investors are prepared for it.

While global equity markets have surged to fresh highs, this high-beta group has been stuck in the mud, grinding sideways and frustrating anyone who’s dared to own it.

Now? Short interest is stretched, bases have been forming for years, and the pressure is building under the surface like a volcano ready to erupt.

In our view, short sellers are about to get steamrolled.

The real opportunity is in identifying which individual stocks are best positioned to deliver explosive upside. That’s where our Freshly Squeezed framework comes in.

After applying our framework, we're left with a refined watchlist - the Double-Squeeze Biotech table - featuring the most asymmetric opportunities in the entire industry.

Conditions are ripe for a historic squeeze in biotech. The only question is which stocks will lead the way once the squeeze ignites?

Get a special FREE PREVIEW of the latest Freshly Squeezed Report from All Star Charts — Including 4 High-Conviction Setups Backed by high short interest and breakout charts.